The application covers a once-weekly autoinjector formulation of the anti-amyloid antibody Leqembi (lecanemab), after ... to extend the use of the subcutaneous injector into the induction phase ...

Lecanemab is the result of a strategic ... for maintenance dosing of a subcutaneous auto injection formulation, which is being developed to enhance convenience for patients, was accepted in ...